Latest Headlines

Latest Headlines

Horizon has said it's ready to up its bid, Depomed CEO says. So where's the new offer?

Horizon Pharma has told target Depomed that it's prepared to hike its $2 billion offer for the company and throw in a cash component of up to 25%, according to Depomed chief Jim Schoeneck. And he wants to know where that sweetened offer is.

Mylan CEO Bresch: We want Perrigo--but we don't need it

Perrigo CEO Joseph Papa said this week that he doesn't intend to make it easy for Mylan to pull off a hostile takeover of his company. But the way Mylan sees it, if it loses out, it's not the end of the world.

Chiltern buys Theorem to compete with CRO heavyweights

Two mid-size CROs are slated to merge and contend with the industry's titans, as Chiltern is buying Theorem Clinical Research in a move to strengthen its global presence.

Allergan's brands deliver sales beat in a good sign for generics-free future

On Thursday, Allergan reported earnings for the first full quarter after the company--once known as Actavis--remade itself, buying up its current namesake and dubbing itself a "growth pharma."

Perrigo CEO: Think Mylan's buyout will come easily? Think again

Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan's generics business for $40.5 billion. Mylan's shares plummeted on that news. And now, Perrigo has broken its silence--and the word isn't what Mylan wants to hear.

With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&A

Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics, not to mention a solid biosimilars pipeline.

With more consolidation on tap in generics, who's next to buy and be bought?

Teva's $40.5 billion deal for Allergan's generics business, announced last week, was just the latest to hit a rapidly consolidating generics industry. And while the M&A bug is sweeping through the wider pharma industry, in generics, there's an added factor pushing copycats to join hands.

Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offer

On Tuesday, Shire went public with a $30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's not happening.

Shire CEO Ornskov faces a tough slog in quest to acquire Baxalta

Baxalta execs didn't like the idea of a $30 billion all-share Shire buyout when they heard it the first time on July 10--and they didn't warm to it at all when Shire decided to go public with the offer Tuesday morning.

Philips on the hunt for more deals amid HealthTech refocus

Royal Philips has been on the dealmaking circuit since separating out its lighting business last year, scouting out partnerships and hospital contracts to beef up its new consumer healthcare unit. And the company is hungry for more M&A, working with Bank of America to scout out medical device acquisitions to bolster its offerings.